Augustine治疗公司指定新的主席和首席执行官,确保为临床试验提供78M欧元的资金。 Augustine Therapeutics names new Chair and CEO, secures €78M funding for clinical trials.

Augustine Augustine治疗公司是一家生物技术公司,开发神经退化和心血管代谢疾病的治疗方法,已任命有经验的生命科学执行官Pascale Witz担任董事会主席。 Augustine Therapeutics, a biotech firm developing treatments for neurodegenerative and cardio-metabolic diseases, has appointed Pascale Witz, a seasoned life sciences executive, as Chair of its Board of Directors. 该公司还获得了7 800万欧元的资金,反映出投资者对其HDAC6抑制剂的信心。 The company has also secured €78 million in funding, reflecting investor confidence in its HDAC6 inhibitors. 此外,Gerhard Koenig已被任命为CEO,因为该公司准备进入临床试验。 Additionally, Gerhard Koenig has been named CEO as the company prepares to enter clinical trials.